Aerie Pharmaceuticals Inc (AERI) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $66. H.C. Wainwright advised their investors in a research report released on Sep 20, 2016.
Many Wall Street Analysts have commented on Aerie Pharmaceuticals Inc. Company shares were Reiterated by RBC Capital Mkts on Sep 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 55 from a previous price target of $51 .Company shares were Reiterated by Needham on Sep 15, 2016 to “Buy”, Firm has raised the Price Target to $ 52 from a previous price target of $45 .Company shares were Reiterated by Stifel on Sep 15, 2016 to “Buy”, Firm has raised the Price Target to $ 50 from a previous price target of $40 .
Aerie Pharmaceuticals Inc opened for trading at $31.01 and hit $35.25 on the upside on Friday, eventually ending the session at $34.87, with a gain of 13.92% or 4.26 points. The heightened volatility saw the trading volume jump to 10,250,248 shares. Company has a market cap of $973 M.
In a different news, on Apr 26, 2016, Gerald D. Cagle (director) purchased 4,646 shares at $18.24 per share price. According to the SEC, on Apr 16, 2015, Anand Mehra (director) sold 425,000 shares at $33.76 per share price.
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.